Article
Medicine, Research & Experimental
Xi Chen, Yechen Wu, Xinan Wang, Chengdang Xu, Licheng Wang, Jingang Jian, Denglong Wu, Gang Wu
Summary: This study identified CDK6 as a potential gene associated with the occurrence of EnzR CRPC using bioinformatic methods. The study also revealed that suppression of CDK6 expression may be helpful in treating EnzR CRPC.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)
Article
Multidisciplinary Sciences
Mamta Parikh, Chengfei Liu, Chun-Yi Wu, Christopher P. Evans, Marc Dall'Era, Daniel Robles, Primo N. Lara, Neeraj Agarwal, Allen C. Gao, Chong-Xian Pan
Summary: The study aimed to evaluate the efficacy and tolerability of a novel reformulated orally-bioavailable niclosamide in combination with abiraterone and prednisone for castration-resistant prostate cancer. The results showed that this combination therapy demonstrated good tolerability and treatment response in patients, warranting further research.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Eliot B. Blatt, Karla Parra, Antje Neeb, Lorenzo Buroni, Denisa Bogdan, Wei Yuan, Yunpeng Gao, Collin Gilbreath, Alec Paschalis, Suzanne Carreira, Ralph J. DeBerardinis, Ram S. Mani, Johann S. de Bono, Ganesh V. Raj
Summary: Therapy resistance to enzalutamide, a second-generation androgen receptor antagonist, is common in advanced prostate cancer (PCa) patients. This resistance is associated with higher levels of reactive oxygen species (ROS) and enhanced glutamine metabolism. Inhibiting glutamine metabolism or targeting antioxidant pathways can block the growth of enzalutamide-resistant PCa cells.
Article
Oncology
Orazio Caffo, Cinzia Ortega, Franco Nole, Donatello Gasparro, Claudia Mucciarini, Michele Aieta, Vittorina Zagonel, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Antonello Veccia, Erica Palesandro, Elena Verri, Sebastiano Buti, Giorgia Razzini, Giovanni Bozza, Marco Maruzzo, Chiara Ciccarese, Giuseppe Schepisi, Sabrina Rossetti, Francesca Maines, Stefania Kinspergher, Lucia Fratino, Paola Ermacora, Maurizio Nicodemo, Monica Giordano, Donata Sartori, Daniela Scapoli, Roberto Sabbatini, Giovanni Lo Re, Franco Morelli, Alessandro D'Angelo, Isabella Vittimberga, Paolo Lippe, Francesco Carrozza, Caterina Messina, Luca Galli, Francesca Valcamonico, Camillo Porta, Giovanni Pappagallo, Massimo Aglietta
Summary: The combination of enzalutamide and docetaxel appears to be more clinically beneficial than docetaxel alone in previously untreated mCRPC patients, although serious adverse events were more frequent. The results suggest that first-line treatment with this combination could lead to additional clinical benefit when prompt and prolonged disease control is needed. However, caution should be exercised due to the study's phase II design and the lack of overall survival benefit.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Ke Gao, Xiaoshun Li, Jianxin Ni, Bin Wu, Jiaheng Guo, Rui Zhang, Guojun Wu
Summary: This article introduces the roles of dysregulation of different subclasses of non-coding RNAs (ncRNAs) in the development of castration-resistant prostate cancer (CRPC) progression and Enzalutamide (Enz) resistance. The mechanisms of Enz resistance, including AR-splice variant-7 (AR-V7), mutations, circRNAs, and lncRNAs that act as miRNA sponges, are discussed. The contributions of epithelial-mesenchymal transition and glucose metabolism to Enz resistance are also highlighted. The article summarizes the different mechanisms of miRNAs, lncRNAs, and circRNAs in the progression of CRPC and Enz resistance, and discusses future therapeutic strategies against Enz resistance.
Article
Nanoscience & Nanotechnology
Mariana Morais, Vera Machado, Francisca Dias, Patricia Figueiredo, Carlos Palmeira, Gabriela Martins, Rui Fernandes, Ana Rita Malheiro, Kirsi S. Mikkonen, Ana Luisa Teixeira, Rui Medeiros
Summary: The glucose-functionalized silver nanoparticles showed promising cytotoxic effects on CRPC cells, indicating their potential as a future therapeutic approach for patients with PCa resistant to hormone therapy or metastatic disease.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Oncology
Jing Wei, Lijuan Yin, Jingjing Li, Jing Wang, Tianjie Pu, Peng Duan, Tzu-Ping Lin, Allen C. Gao, Boyang Jason Wu
Summary: The study reveals a reciprocal regulatory circuit between MAOA and AR in prostate cancer, with implications for cancer development and growth, particularly CRPC. Targeting MAOA may enhance the efficacy of AR-targeted therapies.
Article
Chemistry, Multidisciplinary
Jia-Luo Huang, Xue-Long Yan, Wei Li, Run-Zhu Fan, Shen Li, Jianghe Chen, Zhenhua Zhang, Jun Sang, Lu Gan, Gui-Hua Tang, Hongwu Chen, Junjian Wang, Sheng Yin
Summary: This study identified a highly potent importin-beta 1 inhibitor DD1, which selectively inhibited the growth and survival of CRPC cells and completely blocked tumor growth. Mechanistic studies showed that DD1 reduced the nuclear accumulation of key CRPC drivers, shutting down their downstream oncogenic signaling. These findings suggest that importin-beta 1 is an effective therapeutic target in CRPC and DD1 can be developed as a potential treatment for this disease.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Review
Endocrinology & Metabolism
Xiangyun You, Shan Huang, Xin'an Wang, Cheng Yi, Niandong Gong, Junfeng Yu, Chengdang Xu, Zhendong Xiang
Summary: Bipolar androgen therapy (BAT) is an effective and safe treatment for castration-resistant prostate cancer patients who have progressed after abiraterone or enzalutamide. BAT can restore patients' sensitivity to subsequent endocrine therapy and improve overall survival and quality of life. Meta-analysis results showed that patients who underwent BAT achieved a PSA50 response rate of 27%, an ORR of 34%, and a grade >= 3 adverse event incidence of 14%.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Rahul Aggarwal, Alexander N. Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, Michael A. Carducci
Summary: This study evaluated the safety and efficacy of GS-5829 as a treatment for mCRPC patients. The results showed that the drug was generally tolerated but had limited effectiveness, and there was no clear relationship between dose and plasma concentration.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sanjay Das, Nadine A. Friedrich, James Daniels, G. Cecilia Galvan, Jun Gong, Edwin Posadas, William Aronson, Stephen J. Freedland
Summary: This study compares public interest in FDA-approved drugs for advanced prostate cancer and finds that Bicalutamide remains relatively popular, especially among lower-income individuals, those without health insurance, and in states that did not expand Medicaid.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Medicine, General & Internal
Shabbir M. H. Alibhai, Henriette Breunis, Gregory Feng, Narhari Timilshina, Aaron Hansen, Padraig Warde, Richard Gregg, Anthony Joshua, Neil Fleshner, George Tomlinson, Urban Emmenegger
Summary: This study longitudinally examined cognitive function in older men with metastatic castration-resistant prostate cancer undergoing treatment with docetaxel, abiraterone, enzalutamide, and radium Ra 223. The findings suggest that most older men do not experience significant cognitive decline in attention, executive function, and global cognition regardless of the treatment used.
Article
Oncology
Matthew R. Smith, Shibu Thomas, Michael Gormley, Simon Chowdhury, David Olmos, Stephane Oudard, Felix Y. Feng, Yashoda Rajpurohit, Karen Urtishak, Deborah S. Ricci, Brendan Rooney, Angela Lopez-Gitlitz, Margaret Yu, Alexander W. Wyatt, Mark Li, Gerhardt Attard, Eric J. Small
Summary: The SPARTAN study showed that adding apalutamide to ADT improved survival outcomes in nmCRPC patients, but resistance mechanisms need further evaluation. Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST were significantly associated with poor outcomes in patients who received first subsequent androgen signaling inhibitor treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Sisi Qin, Huanyao Gao, Wootae Kim, Huan Zhang, Yayun Gu, Krishna R. Kalari, Jason P. Sinnwell, Jodi A. Scholz, Fang Xie, Ping Yin, Jia Yu, Bo Qin, Yongxian Zhuang, Lixuan Wei, Winston Tan, Alan H. Bryce, Richard M. Weinshilboum, Liewei Wang
Summary: This study identified three drugs that could potentially be alternative treatments for abiraterone nonresponders in patients with metastatic castration-resistant prostate cancer. Additionally, eleven genes targeted by these drugs were associated with worse outcomes in both PROMOTE and Stand Up To Cancer cohorts. Further clinical investigation is needed to determine the efficacy of these alternative therapies.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Eunjeong Seo, Byula Jee, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Minyong Kang
Summary: In this study, the researchers discovered that the AR-V7/YAP1/TAZ axis represses the expression of SLC22A3, leading to resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). This finding provides new insights into potential treatment targets for prostate cancer.
Review
Urology & Nephrology
Charles Laine, Giorgio Gandaglia, Massimo Valerio, Isabel Heidegger, Igor Tsaur, Jonathan Olivier, Francesco Ceci, Roderick C. N. van den Bergh, Alexander Kretschmer, Constance Thibault, Peter K. Chiu, Derya Tilki, Veeru Kasivisvanathan, Felix Preisser, Fabio Zattoni, Christian Fankhauser, Claudia Kesch, Ignacio Puche-Sanz, Marco Moschini, Benjamin Pradere, Guillaume Ploussard, Giancarlo Marra
Summary: This review aims to investigate the features and optimal management of pN+ cM0 prostate cancer based on registry-based studies. The findings suggest that up to 15% of prostate cancer patients have lymph node invasion. However, the optimal management strategy in this setting is not well characterized. The study results show that adjuvant androgen deprivation therapy and adjuvant radiotherapy have survival benefits compared to observation in certain intermediate-risk categories. Factors such as age, Gleason score, Charlson score, etc. are relevant prognostic factors. The results of this study will contribute to future research in defining the optimal management strategy based on different risk categories.
CURRENT OPINION IN UROLOGY
(2022)
Article
Oncology
Igor Tsaur, Anita Thomas, Michelle Monecke, Marion Zugelder, Jochen Rutz, Timothy Grein, Sebastian Maxeiner, Hui Xie, Felix K. -H. Chun, Florian Rothweiler, Jindrich Cinatl, Martin Michaelis, Axel Haferkamp, Roman A. Blaheta
Summary: The natural compound amygdalin has been shown to inhibit the growth and disseminative properties of taxane-resistant prostate cancer cells. This finding is important for identifying effective treatment options for metastatic prostate cancer.
Review
Medicine, General & Internal
Cristian Surcel, Cristian Mirvald, Robert Stoica, Vasile Cerempei, Isabel Heidegger, Apostolos Labanaris, Igor Tsaur, Catalin Baston, Ioanel Sinescu
Summary: Uretero-arterial fistula (UAF) is a rare but life-threatening complication that requires collaboration between multiple specialties. Angiography is the best diagnostic modality, but there is no definitive imaging technique. Surgical exploration remains the most appropriate treatment option for patients with acute massive bleeding.
Review
Oncology
Alicia-Marie K. Beier, Martin Puhr, Matthias B. Stope, Christian Thomas, Holger H. H. Erb
Summary: Metabolic reprogramming plays an important role in tumor growth and progression, and there are significant metabolic changes in prostate cancer. These metabolic alterations may provide new opportunities for treatment.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Dinah Linke, Lukas Donix, Claudia Peitzsch, Holger H. H. Erb, Anna Dubrovska, Manuel Pfeifer, Christian Thomas, Susanne Fuessel, Kati Erdmann
Summary: This study investigated various approaches targeting ABCB1 to resensitize DTX-resistant prostate cancer cells. It was found that ABCB1 was the only transporter highly upregulated in the resistant cells, and its inhibition and knockdown completely reversed the resistance to DTX. In addition, partial reversal was achieved by inhibiting glycosylation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Andreas Nitsch, Caroline Sander, Benedikt Eggers, Martin Weiss, Eva Egger, Franz-Josef Kramer, Holger H. H. Erb, Alexander Mustea, Matthias B. B. Stope
Summary: This study investigated the use of non-invasive physical plasma (NIPP) in treating renal cell carcinoma (RCC). The results showed that NIPP significantly reduced cell growth and motility of RCC cells, and induced cell death. Cellular analysis revealed increased membrane permeability after NIPP treatment, which may contribute to the inhibition of cancer cell activities. These findings suggest that NIPP treatment could be a promising, innovative, and non-chemical option for RCC therapy.
Article
Pathology
Florian Handle, Martin Puhr, Martina Gruber, Chiara Andolfi, Georg Schaefer, Helmut Klocker, Johannes Haybaeck, Peter De Wulf, Zoran Culig
Summary: The study found that RIO kinase (RIOK)-1, an atypical protein kinase/ATPase, plays a role in the production of ribosomal subunits, cell-cycle progression, and protein recruitment. Overexpression of RIOK1 is associated with malignancies and poor prognosis in patients with cancer. However, its role in prostate cancer is unknown.
AMERICAN JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A. J. Buck, Ron H. J. Mathijssen, Ulrich Jaehde, Silke Gillessen, Markus Joerger
Summary: This study compares the efficacy of cabazitaxel at different doses in patients with metastatic castration-resistant prostate cancer (mCRPC) and finds that individual dose adjustments of cabazitaxel can improve clinical feasibility and survival outcome in patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Eva Juengel, Jochen Rutz, Moritz Meiborg, Sascha D. Markowitsch, Sebastian Maxeiner, Timothy Grein, Anita Thomas, Felix K. -H. Chun, Axel Haferkamp, Igor Tsaur, Olesya Vakhrusheva, Roman A. Blaheta
Summary: This study investigates the effects of mistletoe extracts from four host trees on the growth and proliferation of bladder cancer cells and finds that these extracts significantly inhibit bladder cancer growth.
Article
Biochemistry & Molecular Biology
Gregor Duwe, Lukas Mueller, Christian Ruckes, Nikita Dhruva Fischer, Lisa Johanna Frey, Jan Hendrik Boerner, Niklas Roelz, Maximilian Haack, Peter Sparwasser, Tobias Jorg, Christopher C. M. Neumann, Igor Tsaur, Thomas Hoefner, Axel Haferkamp, Felix Hahn, Rene Mager, Maximilian Peter Brandt
Summary: This study is the first to investigate the correlation between splenic volume and immunotherapy in advanced urothelial carcinoma and renal cell carcinoma. The findings suggest that lower splenic volume after three months of treatment is significantly associated with improved overall survival in patients with renal cell carcinoma.
Article
Biochemistry & Molecular Biology
Dimitri Barski, Igor Tsaur, Mihaly Boros, Jan Brune, Thomas Otto
Summary: This study combines amniotic tissues and methylene blue to explore the neuroprotective effect on early functional outcomes in patients undergoing radical prostatectomy. The findings show early recovery of continence after three months, but no effect on potency. This tissue-engineering strategy is feasible and further prospective comparative studies are warranted.
Article
Urology & Nephrology
Gregor Duwe, Katharina Boehm, Maximilian Haack, Peter Sparwasser, Maximilian Peter Brandt, Rene Mager, Igor Tsaur, Axel Haferkamp, Thomas Hoefner
Summary: Focal therapy (FT) for localized prostate cancer (PCa) is only recommended within the context of clinical trials, and this study aimed to investigate the oncological follow-up and safety data of focal high-intensity focused ultrasound (HIFU) treatment. The results showed that HIFU treatment was feasible in carefully selected patients, but the tumor progression rate was 37.93% with a risk of metastasis, leading to the discontinuation of HIFU usage.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Andrea Eigentler, Florian Handle, Silvia Schanung, Antonia Degen, Hubert Hackl, Holger H. H. Erb, Georgios Fotakis, Julia Hoefer, Christian Ploner, Karin Joehrer, Isabel Heidegger, Andreas Pircher, Werner Klotz, Manfred Herold, Georg Schaefer, Zoran Culig, Martin Puhr
Summary: Despite recent advances in the treatment of metastatic prostate cancer, drug resistance remains a major obstacle. Epithelial glucocorticoid receptor signaling and changes in the tumor microenvironment have been found to play important roles in this process. Investigating the impact of glucocorticoids on stromal receptor signaling is crucial due to their use in prostate cancer treatment.
Article
Urology & Nephrology
Igor Tsaur, Roman A. Blaheta, Robert Dotzauer, Maximilian P. Brandt, Giorgio Gandaglia, Ioanel Sinescu, Cristian Mirvald, Jonathan Olivier, Cristian Surcel
Summary: This study aims to summarize the evidence of focal therapy (FT) in oligometastatic prostate cancer (OMPC). The study found that OMPC has distinct differences in biological behavior and molecular signaling processes compared to polymetastatic disease (PMPC), and there are currently no established biomarkers to accurately identify OMPC. Although data comparing FT to standard care in OMPC are scarce, longer progression-free survival and time to castration resistance have been demonstrated for bone metastatic prostate cancer treated with cryosurgery followed by androgen deprivation therapy (ADT) compared to ADT alone.
WORLD JOURNAL OF UROLOGY
(2023)
Review
Oncology
Isabel Heidegger, Claudia Kesch, Alexander Kretschmer, Igor Tsaur, Francesco Ceci, Massimo Valerio, Derya Tilki, Giancarlo Marra, Felix Preisser, Christian D. Fankhauser, Fabio Zattoni, Peter Chiu, Ignacio Puche-Sanz, Jonathan Olivier, Roderik C. N. van den Bergh, Veeru Kasivisvanathan, Andreas Pircher, Irene Virgolini, Giorgio Gandaglia
Summary: This narrative review article summarizes recent studies investigating predictive and prognostic clinical, imaging-based, and molecular biomarkers to select the most suitable prostate cancer patients for 177Lu-PSMA-617 radioligand therapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
